Skip to main content

Table 5 Combination of treatment at the time of dnDSA (n = 13) and overall MVI outcomes (*Fisher’s exact test p < 0.05)

From: Clinical and histological evolution after de novo donor-specific anti-human leukocyte antigen antibodies: a single centre retrospective study

N = 13

Rituximab

Plasma exchanges

IVIG

Steroid bolus and treatment reinforcement

 

yes

no

yes

no

yes

no

yes

no

MVI reduction (n = 6)

3

3

3

3

0

6*

5

1

No change in MVI (=4)

1

3

1

3

3

1

2

2

MVI progression (n = 3)

2

1

2

1

2

1

1

2

  1. IVIG intravenous immunoglobulins, MVI microvascular inflammation defined as g + ptc score